Cover Image
QR Code

Efficacy and safety of surufatinib plus PD-1/PD-L1 inhibitors as first-line maintenance therapy in extensive-stage small cell lung cancer.

Published in:Holistic Integrative Oncology Vol. 5; no. 1; pp. 1 - 11
Main Authors: Tao, Haitao, Chen, Jianhua, Lv, Dongqing, Wang, Jinliang, Ma, Junxun, Yi, Tienan, Wu, Shikai, Zhou, Xiangdong, Zhang, Xingxing, Chen, Dongmei, Fan, Songhua, Zhong, Chen, Guan, Chunyu, Shi, Michael, Su, Weiguo, Hu, Yi
Format: research tables/charts Journal Article
Published: Springer Nature 7/28/2026
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195685803&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 195685803
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        27314529
        N50T
      jtl: Holistic Integrative Oncology
      issn: 27314529
      maglogo: N
    pubinfo:
      dt: 7/28/2026
      vid: 5
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        195685803
        195685803
        195685803
        10.1007/s44178-026-00281-w
        195685803
      ppf: 1
      ppct: 10
      formats:
      tig:
        atl: Efficacy and safety of surufatinib plus PD-1/PD-L1 inhibitors as first-line maintenance therapy in extensive-stage small cell lung cancer.
      aug:
        au:
          Tao, Haitao
          Chen, Jianhua
          Lv, Dongqing
          Wang, Jinliang
          Ma, Junxun
          Yi, Tienan
          Wu, Shikai
          Zhou, Xiangdong
          Zhang, Xingxing
          Chen, Dongmei
          Fan, Songhua
          Zhong, Chen
          Guan, Chunyu
          Shi, Michael
          Su, Weiguo
          Hu, Yi
        affil: https://ror.org/04gw3ra78 Department of Medical Oncology, Senior Department of Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, 100039, Beijing, China
      sug:
        subj:
          Carcinoma, Non-Small-Cell Lung Drug Therapy
          Tyrosine Kinase Inhibitors Therapeutic Use
          Programmed Cell Death Protein 1 Receptor Antagonists and Inhibitors
          Programmed Cell Death Ligand 1 Antagonists and Inhibitors
          Antineoplastic Agents, Combined Therapeutic Use
          Immunotherapy
          Chemotherapy, Cancer
          Patient Safety
          Drug Efficacy
          Human
          Funding Source
          Male
          Female
          Aged
          Adult
          Middle Age
          Descriptive Statistics
          Confidence Intervals
          Odds Ratio
          Kaplan-Meier Estimator
          Pearson's Correlation Coefficient
          Cancer Patients
          Adverse Drug Event
          Treatment Outcomes
          Disease Progression
          Aged: 65+ years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N